PspA family typing and PCR-based DNA fingerprinting with BOX A1R primer of pneumococci from the blood of patients in the USA with and without sickle cell disease

Epidemiology and Infection

Volumn 133, Issue 1, 2005, Pages 173-178

  Payne, Dorothy B ^a,b   Sun, A ^a   Butler, J C ^c   Singh, S P ^a   Hollingshead, S K ^b   Briles, D E ^b  

^a ALABAMA STATE UNIVERSITY   (United States)

^b University of Alabama at Birmingham   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; DNA FRAGMENT; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; PRIMER DNA; REPETITIVE DNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; BLOOD ANALYSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA FINGERPRINTING; DNA RESPONSIVE ELEMENT; DRUG DESIGN; DRUG INDICATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; INFECTION SENSITIVITY; MALE; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN FAMILY; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SICKLE CELL ANEMIA; STATISTICAL DISTRIBUTION; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BACTERIAL PROTEINS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DNA FINGERPRINTING; FEMALE; HUMANS; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYMERASE CHAIN REACTION; SICKLE CELL TRAIT; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 14044271425     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268804003085     Document Type: Article

References (32)

1. Paton JC. Pathogenesis of pneumococcal disease. Curr Opin Infect Dis 1993; 6: 363-368.
2. Briles DE, Paton JC, Nahm MH, Swiatlo E. Immunity to Streptococcus pneumoniae. In: Cunningham M, Fujinami RS, eds. Effect of microbes on the immune system. Philadelphia: Lippincott-Raven, 2000; 263-280.
3. Wong W-Y, Overturf GE, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect Dis 1992; 14: 1124-1136.
4. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. J Am Med Assoc 2001; 285: 1729-1735.
5. Wilson RE, Krishnamurti L, Kamat D. Management of sickle cell disease in primary care. Clin Pediatr 2003; 42: 753-761.
6. Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis 1999; 14: 191-218.
7. Austrian R. The enduring pneumococcus: unfinished business and opportunities for the future. Microb Drug Resist 1997; 3: 111-115.
8. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994; 265: 1385-1387.
9. Black S, Shinefield H, Fireman BE, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-195.
10. Weintrub PS, Schiffman G, Addiego JE, et al. Long-term follow-up and booster immunization with polyvalent pneumococcal polysaccharide in patients with sickle cell anemia. J Pediatr 1984; 105: 261-263.
11. Jacobson RM, Poland GA. The pneumococcal conjugate vaccine. Minerva Pediatr 2002; 54: 295-303.
12. Briles DE, Ades E, Paton JC, et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000; 68: 796-800.
13. Briles DE, Hollingshead SK, Swiatlo E, et al. Pneumococcal proteins PspA and PspC: their potential for use as vaccines. In: Tomasz A, Austrian R, eds. Molecular biology of pneumococci and pneumococcal diseases. New York: Mary Ann Liebert Inc., 2000: 253-260.
14. Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 2004; 72: 114-122.
15. Hollingshead SK, Becker RS, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000; 68: 5889-5900.
16. Coral MCV, Fonseca N, Castaneda E, Di Fabio JL, Hollingshead SK, Briles DE. Families of pneumococcal surface protein A (PspA) of Streptococcus pneumoniae invasive isolates recovered from Colombian children. Emerg Infect Dis 2001; 7: 832-836.
17. Briles, DE, Hollingshead SK, King J, et al. Immunization of humans with rPspA elicits antibodies, which passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182: 1694-1701.
18. van Belkum A, Sluijuter M, de Groot R, Verbrugh H, Hermans PW. Novel BOX repeat PCR assay for high-resolution typing of Streptococcus pneumoniae strains. J Clin Microbiol 1996; 34: 1176-1179.
19. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam R, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system. J Infect Dis 1996; 174: 986-993.
20. Gray BM, Dillon HC. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis 1986; 5: 201-207.
21. Robinson DA, Hollingshead SK, Musser JM, Parkinson AJ, Briles DE, Crain MJ. The IS1167 insertion sequence is a phenotypically informative marker among isolates of serotype 6B Streptococcus pneumoniae. Mol Evolution 1998; 47: 220.
22. Robinson DA, Turner JS, Facklam RR, et al. Molecular characterization of a globally distributed lineage of serotype 12F Streptococcus pneumoniae causing invasive disease. J Infect Dis 1999; 179: 414-422.
23. Koeuth T, Versalovic J, Lupski JR. Differential subsequence conservation of interspersed repetitive Streptococcus pneumonia Box elements in diverse bacteria. Genome Res 1995; 5: 408-418.
24. Mollerach M, Regueira M, Bonofiglio L, et al. Invasive Streptococcus pneumoniae isolates from Argentinian children: serotypes, families of pneumococcal surface protein A (PspA) and genetic diversity. Epidemiol Infect 2004; 132: 177-184.
25. Dowson CG, Barcus V, King S, Pickerill P, Whatmore A, Yeo M. Horizontal gene transfer and the evolution of resistance and virulence determinants in Streptococcus. Soc Appl Bacteriol Symp Ser 1997; 26: 42S-51S.
26. Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor AE. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada. J Infect Dis 1999; 179: 892-900.
27. Robinson DA, Edwards KM, Waites KB, Briles DE, Crain MJ, Hollingshead SK. Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee. J Infect Dis 2001; 183: 1501-1507.
28. Hermans PWM, Sluijter M, Hoogenboezem T, Heersma H, van Belkum A, de Groot R. Comparative study of five different DNA fingerprint techniques for molecular typing of Streptococcus pneumoniae. J Clin Microbiol 1995; 33: 1606-1612.
29. Crain MJ, Turner JS, Robinson DA, et al. Evidence for the simultaneous expression of two PspAs by a clone of capsular serotype 6B Streptococcus pneumoniae. Microb Pathog 1996; 21: 265-275.
30. Beall B, Gherardi G, Facklam RR, Hollingshead SK. Pneumococcal pspA sequence types of prevalent multi-resistant pneumococcal strains in the United States and of internationally disseminated clones. J Clin Microbiol 2000; 38: 3663-3669.
31. Briles DE, Nabors GS, Brooks-Walter A, Paton J, Hollingshead S. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2001; 19: S87-S95.
32. Nabors GS, Braun PA, Herrmann DJ, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies. Vaccine 2000; 18: 1743-1754.